Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MBX-2982 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MBX-2982 25 mg | EXPERIMENTAL | - |
| MBX-2982 100 mg | EXPERIMENTAL | - |
| MBX-2982 300 mg | EXPERIMENTAL | - |
| Sitagliptin 100 mg | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MBX-2982 | DRUG | tablets and capsule once daily |
| Sitagliptin | DRUG | tablets and capsule once daily |
| placebo | DRUG | tablets and capsule once daily |
Inclusion Criteria: * History of type 2 diabetes of at least 3 months duration * Treatment-naïve (not on any anti-diabetic medication) or treated with a single anti-diabetic agent (excluding insulin, exenatide or other GLP-1 analogs, pioglitazone or rosiglitazone) * HbA1c 7.0-8.5% (inclusive) at sc...
MBX-2982 is an investigational small molecule developed for the treatment of type 2 diabetes. It was studied as a once-daily oral monotherapy in adults with type 2 diabetes. It has not been approved for any indication and remains in clinical development.
MBX-2982 targets GPR119, a G protein-coupled receptor. It acts as a GPR119 agonist. GPR119 is expressed in the pancreas and gastrointestinal tract, where receptor activation is associated with glucose-dependent insulin release and incretin hormone secretion.
MBX-2982 is being developed by Gilead Sciences, Inc., which trades on Nasdaq under the ticker GILD. Gilead holds the asset as part of its metabolic disease pipeline.
MBX-2982 is in Phase 2 development. It is an investigational drug and has not received FDA approval. The Phase 2 program in type 2 diabetes has been completed, and no trials of MBX-2982 are currently active.
MBX-2982 has been evaluated in one completed Phase 2 trial, NCT01035879. That study assessed the efficacy, safety, tolerability, and pharmacokinetics of daily MBX-2982 given as monotherapy for four weeks in patients with type 2 diabetes. It enrolled 100 participants across the United States, Georgia, and India.
NCT01035879 was a randomized, double-blind, placebo-controlled Phase 2 study of MBX-2982 as monotherapy in adults with type 2 diabetes. It enrolled 100 participants aged 18 years and older of any sex, and it did not use biomarker-based patient selection.